X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of this agreement, Almirall will gain a license to utilize EpimAb’s proprietary Fabs-In-Tandem Immunoglobulin (FIT-Ig®) platform technology to generate, develop and commercialize bispecific antibodies, for which Almirall will have exclusive global rights.
Lead Product(s): Bispecific Antibody
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Large molecule
Partner/Sponsor/Collaborator: Almirall
Deal Size: $210.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 12, 2023
Details:
EMB-01(FIT-013a) is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. EMB-01 has demonstrated efficacy in multiple preclinical models.
Lead Product(s): FIT-013a,Osimertinib Mesylate
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 08, 2022
Details:
The EMB-02 Phase 1/2 study is a multi-center, open label, multiple-dose, first in human study to assess the safety and tolerability of EMB-02 in patients with advanced solid tumors.
Lead Product(s): EMB-02
Therapeutic Area: Oncology Product Name: EMB-02
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 06, 2021
Details:
Proceeds from the financing will be used to fund the ongoing clinical development of EMB-01, EMB-02 and EMB-06, and to expand the company’s pipeline of novel bispecific antibodies and other biologics.
Lead Product(s): FIT-013a
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: China Merchants Bank International
Deal Size: $120.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing March 23, 2021
Details:
The data presented in the poster characterizes EMB-01, EpimAb’s lead bispecific antibody candidate developed based the company’s proprietary FIT-Ig® platform to target EGFR and cMet on tumor cells simultaneously.
Lead Product(s): EMB-01
Therapeutic Area: Oncology Product Name: EMB-01
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 22, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
